Since the appearance of the Corona epidemic six months ago, treatments have been sought that can improve survival, especially in the most ill patients. Dexamethasone was the first drug to reduce the risk of death among patients with severe respiratory complications for Covid-19. (It has been Proven to Reduce Mortality and is an Instant Treatment Available at reasonable prices all over the world.)
The researchers' announcement from Oxford University carried detailed results in the global fight against the "Covid 19" epidemic. These results come at a time when both the anti-Covid-19 vaccine is not available, and it provides a low-cost drug to reduce the risk of death by a third among hospital patients who suffer from severe respiratory complications due to infection with Covid-19 infection, according to Al-Sharq Al-Awsat.
The results of this study also presented the feasibility of adopting a meticulous design approach in conducting medical studies of epidemic infections, working to implement them, and following up on the effect of this on patients, and coming up with practical results that can be used in a practical way, despite the short age of it as a therapeutic medical study.
The results of this study also opened the door to further clinical studies of potential beneficial therapeutic treatment with cases of acute and non-respiratory complications of the Covid-19 virus, by moving towards other therapeutic methods, available, working to reset the deformity in the high frequency of the body's immune system reactions with This viral infection.
Oxford University researchers established a randomized evaluation for covid-19 treatment program in March of this year, as a randomized clinical trial to test a range of possible treatments for covid-19 cases, including a low dose of dexamethasone (a drug). Class of steroid medications). The study was abbreviated as "RECOVERY" by taking one of the English words for the title of the study. The letter R is from the prefix "random," the letter E from the prefix "evaluation", the letters C and O and in the COV from the word Covid, and the letters E and R and ERY from the word "cure."
"The low-cost dexamethasone reduces death by up to a third in hospital patients with severe complications for Covid-19 in the respiratory system," the study was headlined in the Oxford University newsletter on June 16th.
The study involved more than 11,500 patients in more than 175 NHS hospitals in the UK.
On June 8th, the "Dexamethasone Therapy Receiving Arm" was completed with the study, including the necessary number of patients to evaluate and determine whether or not the drug has a feasible benefit. The severity of the pathological injury was among the subjects included in the study on degrees, among them were patients whose condition was advanced and required support of the ventilator, patients requiring respiratory treatment to receive oxygen only (without the need for a ventilator), and patients with covid-19 but did not need any Respiratory therapeutic intervention.
Then they were randomly divided into two comparison groups, a group of 2104 patients who received dexamethasone in the amount of 6 milligrams (mg) once daily (either orally or by intravenous injection) for ten days, and a second group of 4321 patients who received care The usual curative alone.
The effectiveness of the drug:
In their results, the researchers noted that the death rate was lower in the group of patients who received dexamethasone compared to patients in the group that did not receive this drug and received the usual treatment care alone. Specifically, the researchers reported by comparison that receiving dexamethasone reduced mortality by one third in patients whose condition was advanced and required ventilator support, as well as reduced mortality by one fifth in patients who were receiving only respiratory oxygen therapy, and there was no clear benefit for receiving it among patients who did not They need any respiratory intervention originally.
The researchers also reported that during 28 days of follow-up to the group of patients who received usual care alone (without dexamethasone), the death rate was the highest in the category of those who needed respiratory support, and the death rate was average in the category of those who needed only oxygen, as well as the 28-day mortality rate was the lowest among those who did not need any respiratory intervention.
(Given the importance of these findings in public Health. we are now working to publish full details as soon as possible,) the Researchers Said.
Excellent result:
The researchers' announcement from Oxford University carried detailed results in the global fight against the "Covid 19" epidemic. These results come at a time when both the anti-Covid-19 vaccine is not available, and it provides a low-cost drug to reduce the risk of death by a third among hospital patients who suffer from severe respiratory complications due to infection with Covid-19 infection, according to Al-Sharq Al-Awsat.
The results of this study also presented the feasibility of adopting a meticulous design approach in conducting medical studies of epidemic infections, working to implement them, and following up on the effect of this on patients, and coming up with practical results that can be used in a practical way, despite the short age of it as a therapeutic medical study.
The results of this study also opened the door to further clinical studies of potential beneficial therapeutic treatment with cases of acute and non-respiratory complications of the Covid-19 virus, by moving towards other therapeutic methods, available, working to reset the deformity in the high frequency of the body's immune system reactions with This viral infection.
Oxford University researchers established a randomized evaluation for covid-19 treatment program in March of this year, as a randomized clinical trial to test a range of possible treatments for covid-19 cases, including a low dose of dexamethasone (a drug). Class of steroid medications). The study was abbreviated as "RECOVERY" by taking one of the English words for the title of the study. The letter R is from the prefix "random," the letter E from the prefix "evaluation", the letters C and O and in the COV from the word Covid, and the letters E and R and ERY from the word "cure."
"The low-cost dexamethasone reduces death by up to a third in hospital patients with severe complications for Covid-19 in the respiratory system," the study was headlined in the Oxford University newsletter on June 16th.
The study involved more than 11,500 patients in more than 175 NHS hospitals in the UK.
On June 8th, the "Dexamethasone Therapy Receiving Arm" was completed with the study, including the necessary number of patients to evaluate and determine whether or not the drug has a feasible benefit. The severity of the pathological injury was among the subjects included in the study on degrees, among them were patients whose condition was advanced and required support of the ventilator, patients requiring respiratory treatment to receive oxygen only (without the need for a ventilator), and patients with covid-19 but did not need any Respiratory therapeutic intervention.
Then they were randomly divided into two comparison groups, a group of 2104 patients who received dexamethasone in the amount of 6 milligrams (mg) once daily (either orally or by intravenous injection) for ten days, and a second group of 4321 patients who received care The usual curative alone.
The effectiveness of the drug:
In their results, the researchers noted that the death rate was lower in the group of patients who received dexamethasone compared to patients in the group that did not receive this drug and received the usual treatment care alone. Specifically, the researchers reported by comparison that receiving dexamethasone reduced mortality by one third in patients whose condition was advanced and required ventilator support, as well as reduced mortality by one fifth in patients who were receiving only respiratory oxygen therapy, and there was no clear benefit for receiving it among patients who did not They need any respiratory intervention originally.
The researchers also reported that during 28 days of follow-up to the group of patients who received usual care alone (without dexamethasone), the death rate was the highest in the category of those who needed respiratory support, and the death rate was average in the category of those who needed only oxygen, as well as the 28-day mortality rate was the lowest among those who did not need any respiratory intervention.
(Given the importance of these findings in public Health. we are now working to publish full details as soon as possible,) the Researchers Said.
Excellent result:
"Dexamethasone is the first drug to show improved survival in Covid-19. This is a very welcome result," commented Peter Hurby, professor of emerging infectious diseases at Oxford University and a leading researcher in the study. The benefit of survival is clear and significant in those patients with enough disease to need oxygen therapy, so dexamethasone should now become a standard of care in these patients. (Dexamethasone is inexpensive - is on the shelf and can be used immediately to save lives around the world.)
Martin Landrae, professor of medicine and epidemiology at Oxford University and a leading researcher in the study, commented: “Since the advent of Covid-19 six months ago, treatments have been sought that could improve survival, especially in the most ill patients. And in these preliminary results from the recovery study is very clear - dexamethasone reduces the risk of death among patients with severe respiratory complications for Covid-19. It is a global disease - it is wonderful that the first proven treatment to reduce mortality is an immediate and affordable treatment available throughout the world".
Degrees of injuries:
According to the approved medical classification for cases of viral infection with Covid-19 confirmed by the result of the PCR examination, there are five degrees for the cases of infected patients, namely:
• Asymptomatic. It is a carrier of the disease because it can cause infection and others infected with the viral disease accordingly.
•Ild to moderate to moderate Mild-Moderate. That is, the patient has symptoms (such as fever, cough, etc.), but the condition does not require oxygen therapy and there is no evidence of pneumonia.
• Sever severely affected. Patients who have one or more of the following symptoms and signs: respiratory rate more than 30 times per minute for adults, blood saturated oxygen 93 percent or less, x-rays show fluid leaching in the lung by more than 50 percent during 24 to 48 hours.
• Critical. Patients who have one or more of the following symptoms and signs: ARDS, Sepsis, Altered Consciousness, Multi - Organ Failure.
Steroid drug:
Dexamethasone was originally a steroid class that primarily works to reduce the severity of body immune system reactions, and researchers have previously conflicted opinions about its usefulness in treating some other previous types of respiratory viral infections such as SARS in 2003. But the results of this new study It has demonstrated its clear utility in reducing mortality.
In addition to age, or an associated infection with chronic diseases such as diabetes, high blood pressure, heart disease or cancer, as factors that increase the severity of viral diseases, the intensity of the reactions of the body's immune system with the viral infection and the extent of its discipline, another important factor, such as excessive excretion of compounds Cytokines and interferons, and in the production of antibodies and hyperactivity of T cells, which may have pathological effects that are not controlled on the whole body and threaten the stability of the state of health in it, as well as on the coherence of the functional performance of several members of the body such as the lungs, liver, kidneys and circulatory system. Hence you may benefit from receiving certain types and measured doses of the steroid group of drugs, of which one is dexamethasone.
Martin Landrae, professor of medicine and epidemiology at Oxford University and a leading researcher in the study, commented: “Since the advent of Covid-19 six months ago, treatments have been sought that could improve survival, especially in the most ill patients. And in these preliminary results from the recovery study is very clear - dexamethasone reduces the risk of death among patients with severe respiratory complications for Covid-19. It is a global disease - it is wonderful that the first proven treatment to reduce mortality is an immediate and affordable treatment available throughout the world".
Degrees of injuries:
According to the approved medical classification for cases of viral infection with Covid-19 confirmed by the result of the PCR examination, there are five degrees for the cases of infected patients, namely:
• Asymptomatic. It is a carrier of the disease because it can cause infection and others infected with the viral disease accordingly.
•Ild to moderate to moderate Mild-Moderate. That is, the patient has symptoms (such as fever, cough, etc.), but the condition does not require oxygen therapy and there is no evidence of pneumonia.
• Sever severely affected. Patients who have one or more of the following symptoms and signs: respiratory rate more than 30 times per minute for adults, blood saturated oxygen 93 percent or less, x-rays show fluid leaching in the lung by more than 50 percent during 24 to 48 hours.
• Critical. Patients who have one or more of the following symptoms and signs: ARDS, Sepsis, Altered Consciousness, Multi - Organ Failure.
Steroid drug:
Dexamethasone was originally a steroid class that primarily works to reduce the severity of body immune system reactions, and researchers have previously conflicted opinions about its usefulness in treating some other previous types of respiratory viral infections such as SARS in 2003. But the results of this new study It has demonstrated its clear utility in reducing mortality.
In addition to age, or an associated infection with chronic diseases such as diabetes, high blood pressure, heart disease or cancer, as factors that increase the severity of viral diseases, the intensity of the reactions of the body's immune system with the viral infection and the extent of its discipline, another important factor, such as excessive excretion of compounds Cytokines and interferons, and in the production of antibodies and hyperactivity of T cells, which may have pathological effects that are not controlled on the whole body and threaten the stability of the state of health in it, as well as on the coherence of the functional performance of several members of the body such as the lungs, liver, kidneys and circulatory system. Hence you may benefit from receiving certain types and measured doses of the steroid group of drugs, of which one is dexamethasone.
However, the explanation for this apparent therapeutic feasibility of dexamethasone, and the mechanism for obtaining this, remains a topic of research for physicians. Understanding this may lead to an expansion of research into other drugs that may be a useful means of mitigating complications and pathogenic effects of viral infection.
0 Comments
Thank You, Informative